Datapoint: Gilead Scores Expanded Hep B Nod for Vemlidy

The FDA last week expanded Gilead Sciences’ chronic hepatitis B virus (HBV) drug Vemlidy’s label to include pediatric patients 12 and older with compensated liver disease. The drug was first approved in 2016. As of November 2022, 91% of insured lives have covered or better access to Vemlidy, with 25% of lives having preferred access to the drug without utilization management restrictions.

SOURCE: MMIT Analytics, as of 11/7/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 6

Datapoint: United Projects 9% MA Growth in 2023

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 5

Datapoint: EmblemHealth Subsidiary Pulls Out of Connecticut Small Group Market

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 1

Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today